{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:49:01Z","timestamp":1792511341423,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ctrv.2025.103060","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:40:36Z","timestamp":1765006836000},"page":"103060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Renal adverse events associated with cyclin-dependent kinase 4\/6 inhibitors"],"prefix":"10.1016","volume":"142","author":[{"given":"Hassan","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimda","family":"Wanchoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-0524","authenticated-orcid":false,"given":"Kenar D.","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103060_b0005","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","author":"Ferlay","year":"2021","journal-title":"Int J Cancer."},{"key":"10.1016\/j.ctrv.2025.103060_b0010","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.ctrv.2025.103060_b0015","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1056\/NEJM200106283442607","article-title":"Side effects of adjuvant treatment of breast cancer","volume":"344","author":"Shapiro","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ctrv.2025.103060_b0020","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/2594","article-title":"Understanding the cell cycle","volume":"4","author":"Nurse","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103060_b0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s12094-006-0193-7","article-title":"Therapeutic opportunities to control tumor cell cycles","volume":"8","author":"Malumbres","year":"2006","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2025.103060_b0030","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1098\/rstb.2011.0274","article-title":"The cell cycle","volume":"366","author":"Hunt","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.ctrv.2025.103060_b0035","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jnci\/djs002","article-title":"Multiple roles of cyclin-dependent kinase 4\/6 inhibitors in cancer therapy","volume":"104","author":"Roberts","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2025.103060_b0040","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update","author":"Burstein","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ctrv.2025.103060_b0050","article-title":"Association between cyclin-dependent kinase 4\/6 inhibitors and nephrotoxicity in patients with breast cancer","volume":"27","author":"Cui","year":"2024","journal-title":"A Systematic Review and meta-analysis. iScience."},{"key":"10.1016\/j.ctrv.2025.103060_b0055","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2025.103060_b0060","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1158\/1078-0432.CCR-17-2369","article-title":"FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor\u2013 Positive, HER2-Negative Advanced or Metastatic Breast Cancer","volume":"24","author":"Shah","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctrv.2025.103060_b0065","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1158\/1078-0432.CCR-23-1133","article-title":"FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer","volume":"29","author":"Gao","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctrv.2025.103060_b0070","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1200\/JCO.23.00615","article-title":"US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer","volume":"41","author":"Royce","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0075","article-title":"Dalpiciclib in advanced breast cancer","author":"Chen","year":"202324578","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0080","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ctrv.2025.103060_b0085","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ctrv.2025.103060_b0090","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR\u00fe\/HER2-advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol."},{"issue":"8","key":"10.1016\/j.ctrv.2025.103060_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101604","article-title":"PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study","volume":"14","author":"Avc\u0131","year":"2023","journal-title":"J. Geriatr Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0100","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.seminoncol.2024.01.003","article-title":"Real-world experience with CDK4-6 inhibition in the old and oldest old with a diagnosis of breast cancer","volume":"51","author":"Sobrini-Morillo","year":"2024","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0105","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10549-020-05755-7","article-title":"Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+\/HER2- advanced breast cancer (PALOMA-1, TRIO-18)","volume":"183","author":"Finn","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctrv.2025.103060_b0110","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0115","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1200\/JCO.20.03639","article-title":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial","volume":"39","author":"Loibl","year":"2021","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0120","doi-asserted-by":"crossref","first-page":"e1339","DOI":"10.1002\/onco.13833","article-title":"Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist."},{"key":"10.1016\/j.ctrv.2025.103060_b0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2022.03.006","article-title":"Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study","volume":"168","author":"Mart\u00edn","year":"2022","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ctrv.2025.103060_b0130","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"DAWNA-1 Study Consortium. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat Med."},{"key":"10.1016\/j.ctrv.2025.103060_b0135","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1200\/JCO.23.00126","article-title":"PALLAS Groups and Investigators. Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial","volume":"41","author":"Pfeiler","year":"2023","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0140","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejca.2021.11.010","article-title":"Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive\/HER2- advanced breast cancer: GEICAM\/2014-12 (FLIPPER)","volume":"161","author":"Albanell","year":"2022","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ctrv.2025.103060_b0145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cas.15600","article-title":"Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2","volume":"114","author":"Toi","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ctrv.2025.103060_b0150","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s12282-021-01295-0","article-title":"Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"29","author":"Takahashi","year":"2022","journal-title":"Breast Cancer."},{"key":"10.1016\/j.ctrv.2025.103060_b0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.farma.2023.08.006","article-title":"Abemaciclib as adjuvant treatment for high-risk early breast cancer","volume":"48","author":"Andrades","year":"2024","journal-title":"Farm Hosp."},{"key":"10.1016\/j.ctrv.2025.103060_b0160","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920963925","article-title":"MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2-advanced breast cancer: the multinational randomized phase III study","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther. Adv Med Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0165","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ctrv.2025.103060_b0170","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+\/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2025.103060_b0175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ctrv.2025.103060_b0180","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0185","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/23993693221085285","article-title":"Ribociclib-induced pseudo-acute kidney injury","volume":"6","author":"Sy-Go","year":"2022","journal-title":"J Onco-Nephrol."},{"key":"10.1016\/j.ctrv.2025.103060_b0190","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ekir.2021.11.033","article-title":"Clinicopathologic features of acute kidney injury associated with CDK4\/6 inhibitors","volume":"7","author":"Gupta","year":"2022","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.ctrv.2025.103060_b0195","first-page":"e1575","article-title":"Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report","volume":"5","author":"Lagampan","year":"2022","journal-title":"Cancer Rep (Hoboken)."},{"key":"10.1016\/j.ctrv.2025.103060_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2024.1389562","article-title":"Case report: A case of pseudo-acute kidney injury due to cyclin-dependent kinase inhibitor","volume":"4","author":"Errabelli","year":"2024","journal-title":"Front Nephrol."},{"key":"10.1016\/j.ctrv.2025.103060_b0205","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1177\/10781552211007202","article-title":"Ribociclib induced acute kidney injury: A case report","volume":"27","author":"Gulturk","year":"2021","journal-title":"J Oncol Pharm Pract."},{"key":"10.1016\/j.ctrv.2025.103060_b0210","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/23993693211021420","article-title":"An elevated serum creatinine in a patient receiving palbociclib","volume":"5","author":"Bonilla","year":"2021","journal-title":"J. Onco-Nephrol."},{"key":"10.1016\/j.ctrv.2025.103060_b0215","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s12882-025-04442-3","article-title":"Abemaciclib-associated acute interstitial nephritis successfully treated with glucocorticoids: a case report and literature review","volume":"26","author":"Kumano","year":"2025","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ctrv.2025.103060_b0220","doi-asserted-by":"crossref","DOI":"10.1177\/23993693241232733","article-title":"Palbociclib-associated nephrotoxicity in a patient with breast cancer","author":"Tang","year":"2024","journal-title":"J Onco-Nephrol."},{"key":"10.1016\/j.ctrv.2025.103060_b0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41523-023-00576-5","article-title":"Adverse kidney outcomes of CDK 4\/6 inhibitors for metastatic breast cancer","volume":"9","author":"Hanna","year":"2023","journal-title":"NPJ Breast Cancer."},{"key":"10.1016\/j.ctrv.2025.103060_b0230","article-title":"Adverse event profiles of CDK4\/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system. Ther Adv","volume":"15","author":"Shen","year":"2024","journal-title":"Drug Saf."},{"key":"10.1016\/j.ctrv.2025.103060_b0235","doi-asserted-by":"crossref","first-page":"28143","DOI":"10.1038\/s41598-024-79663-x","article-title":"The deleterious effects of CDK4\/6 inhibition on renal recovery post-acute kidney injury","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci Rep."},{"issue":"7","key":"10.1016\/j.ctrv.2025.103060_b0240","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O'Leary","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"issue":"5","key":"10.1016\/j.ctrv.2025.103060_b0245","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/cpt.1296","article-title":"Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate","volume":"105","author":"Chappell","year":"2019","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"10.1016\/j.ctrv.2025.103060_b0250","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist."},{"key":"10.1016\/j.ctrv.2025.103060_b0255","doi-asserted-by":"crossref","unstructured":"Wekking D, Lambertini M, Dess\u0131 M, Denaro N, Bardanzellu F, Garrone O, Scartozzi M, Solinas C. CDK4\/6 inhibitors in the treatment of metastatic breast cancer: Focus on toxicity and safety. Semin Oncol. 2023. 50, 131\u2013139.doi.10.1053\/j.seminoncol.2024.01.002.","DOI":"10.1053\/j.seminoncol.2024.01.002"},{"key":"10.1016\/j.ctrv.2025.103060_b0260","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1158\/1538-7445.AM2015-3101","article-title":"Abstract 3101: In-vitro characterization of Abemaciclib pharmacology in ER+ breast cancer cell lines","volume":"75","author":"Lallena","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctrv.2025.103060_b0265","first-page":"1784","article-title":"Palbociclib induces cell cycle arrest and senescence of human renal tubular epithelial cells in vitro","volume":"40","author":"Huang","year":"2020","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao."},{"key":"10.1016\/j.ctrv.2025.103060_b0270","doi-asserted-by":"crossref","unstructured":"Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LJ, Schlatter E, Chen T, Ciarimboli G, Sparreboom A. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4\/6 and OCT2 functions.Proc Natl Acad Sci U S A. 2015;112:5231-5236. doi: 10.1073\/pnas.1424313112.","DOI":"10.1073\/pnas.1424313112"},{"key":"10.1016\/j.ctrv.2025.103060_b0275","doi-asserted-by":"crossref","first-page":"F379","DOI":"10.1152\/ajprenal.00475.2013","article-title":"CDK4\/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury","volume":"306","author":"DiRocco","year":"2014","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.ctrv.2025.103060_b0280","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/imj.14629","article-title":"Association between ribociclib and changes in creatinine in patients with hormone receptor positive metastatic breast cancer","volume":"49","author":"Wilson","year":"2019","journal-title":"Intern Med J."},{"key":"10.1016\/j.ctrv.2025.103060_b0285","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/biom13071075","article-title":"Should Cystatin C eGFR Become Routine Clinical Practice?","volume":"13","author":"Spencer","year":"2023","journal-title":"Biomolecules."},{"key":"10.1016\/j.ctrv.2025.103060_b0290","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","article-title":"A Phase I Study of the Cyclin-Dependent Kinase 4\/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas","volume":"22","author":"Infante","year":"2016","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2025.103060_b0295","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+\/HER2- Metastatic Breast Cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.ctrv.2025.103060_b0300","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000499534","article-title":"Management of adverse events due to cyclin-dependent kinase 4\/6 inhibitors","volume":"14","author":"Ettl","year":"2019","journal-title":"Breast Care (Basel)."},{"key":"10.1016\/j.ctrv.2025.103060_b0305","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4\/6 Inhibitors in Patients With Metastatic Breast Cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.ctrv.2025.103060_b0310","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamaoncol.2015.4701","article-title":"Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development","volume":"2","author":"Clark","year":"2016","journal-title":"JAMA Oncol."},{"issue":"4 Suppl 1","key":"10.1016\/j.ctrv.2025.103060_b0315","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1524-6175.2006.04482.x","article-title":"Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics","volume":"7","author":"Sica","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ctrv.2025.103060_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102956","article-title":"Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4\/6 inhibitors: A comprehensive review","volume":"137","author":"Sahin","year":"2025","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ctrv.2025.103060_b0325","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(95)91618-0","article-title":"Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation","volume":"346","author":"Stewart","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103060_b0330","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1600-6143.2007.01908.x","article-title":"Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients","volume":"7","author":"Webster","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ctrv.2025.103060_b0335","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","article-title":"Cancer after kidney transplantation in the United States","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ctrv.2025.103060_b0340","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1046\/j.0306-5251.2001.bjcp1558.doc.x","article-title":"Hospital prescribing errors: epidemiological assessment of predictors","volume":"53","author":"Fijn","year":"2002","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.ctrv.2025.103060_b0345","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jama.1997.03540280039031","article-title":"Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality","volume":"277","author":"Classen","year":"1997","journal-title":"JAMA."},{"key":"10.1016\/j.ctrv.2025.103060_b0350","unstructured":"Available at https:\/\/www.drugs.com\/Accessed October 14, 2025."},{"key":"10.1016\/j.ctrv.2025.103060_b0355","unstructured":"Palbociclib Prescribing Information. Available at http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id5 2191#S14. Accessed May 19, 2017. U.S."},{"key":"10.1016\/j.ctrv.2025.103060_b0360","unstructured":"Food & Drug Administration C for DE and Drug Interactions & Labeling - Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664.htm.Accessed September 25, 2016."},{"key":"10.1016\/j.ctrv.2025.103060_b0365","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ctrv.2025.103060_b0370","unstructured":"Kisqali (ribociclib) Prescribing Information. Available at https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/kisqali.pdf.AccessedMarch 20, 2017."},{"key":"10.1016\/j.ctrv.2025.103060_b0375","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctrv.2025.103060_b0380","unstructured":"Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208716s000lbl.pdf."},{"key":"10.1016\/j.ctrv.2025.103060_b0385","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40262-022-01206-2","article-title":"Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials","volume":"62","author":"Ji","year":"2023","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"10.1016\/j.ctrv.2025.103060_b0390","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00280-020-04163-4","article-title":"Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function","volume":"86","author":"Yu","year":"2020","journal-title":"Cancer Chemother Pharmacol."},{"issue":"17","key":"10.1016\/j.ctrv.2025.103060_b0395","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.3390\/ijms21176350","article-title":"CDK4\/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions","volume":"21","author":"Roncato","year":"2020","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.ctrv.2025.103060_b0400","unstructured":"https:\/\/medicarcp.com\/website\/pdf\/spc\/8521%20-%20en.pdf."},{"issue":"4","key":"10.1016\/j.ctrv.2025.103060_b0405","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s10637-025-01564-1","article-title":"Pharmacokinetics, efficacy and safety of palbociclib and fulvestrant in a patient with hormone receptor-positive, human epidermal growth factor receptor 2 negative metastatic breast cancer with end-stage renal disease undergoing hemodialysis: A case report","volume":"43","author":"Takakura","year":"2025","journal-title":"Invest New Drugs."},{"issue":"8","key":"10.1016\/j.ctrv.2025.103060_b0410","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/jcph.1856","article-title":"Ribociclib Population Pharmacokinetics and Pharmacokinetic\/Pharmacodynamic Analysis of Neutrophils in Cancer Patients","volume":"61","author":"Lu","year":"2021","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"10.1016\/j.ctrv.2025.103060_b0415","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40262-022-01206-2","article-title":"Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials","volume":"62","author":"Ji","year":"2023","journal-title":"Clin Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ctrv.2025.103060_b0420","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40262-023-01338-z","article-title":"Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4\/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer","volume":"63","author":"Ji","year":"2024","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.ctrv.2025.103060_b0425","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/209092Orig1s001.pdf?."},{"key":"10.1016\/j.ctrv.2025.103060_b0430","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/209935s014lbl.pdf?."},{"key":"10.1016\/j.ctrv.2025.103060_b0435","unstructured":"https:\/\/www.cancercareontario.ca\/fr\/drugformulary\/drugs\/monograph\/54136?."},{"issue":"12","key":"10.1016\/j.ctrv.2025.103060_b0440","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.ctrv.2025.103060_b0445","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214200s004lbl.pdf?."},{"key":"10.1016\/j.ctrv.2025.103060_b0450","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/214200Orig1s000ClinPharmR.pdf?."},{"issue":"40","key":"10.1016\/j.ctrv.2025.103060_b0455","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035487","article-title":"CDK4\/6 inhibitors for hormone receptor-positive\/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessment","volume":"102","author":"Gu","year":"2023","journal-title":"Medicine (Baltimore)."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:04:04Z","timestamp":1767168244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":91,"alternative-id":["S0305737225001823"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103060","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal adverse events associated with cyclin-dependent kinase 4\/6 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103060"}}